News | January 08, 2009

Bayer Schering Pharma Deal Targets Molecular Imaging

January 8, 2009 – Bayer Schering Pharma AG and Hamamatsu Photonics K.K., Japan have signed a licensing agreement for the use of novel substances in the field of molecular imaging for cancer, allowing the company to expand its existing molecular imaging portfolio in the area of cancer.

In the agreement, Bayer Schering Pharma acquires the worldwide exclusive rights for research, development and commercialization of a group of molecules that specifically bind to malignant tumor cells. The company anticipates that used in combination with positron emission tomography (PET), these tracers could potentially improve the diagnosis of a variety of cancers.

The tracers are labeled with a short-life radionuclide and thus can be employed for PET imaging. PET is a nuclear medicine imaging procedure, with which molecular processes can be visualized in vivo, for example those in tumor cells. In contrast to the presently common procedures in PET imaging of cancer, these new PET tracers could help to possibly better differentiate malignant tumors from benign tissue alterations and to allow a more precise staging of the cancer.

"We have developed the novel tumor PET tracer based on a substance to be incorporated into tumor cells through the carrier molecules highly expressed on the tumor cell membrane. Since the chemical structure of this PET tracer is designed not to be identified by the carrier system on the normal cell membrane, the location of tumor tissue could be detected with high contrast in tumor animal models with PET,” said Hideo Tsukada, M.D., manager of the PET Center at Hamamatsu Photonics.

Find more information: www.bayerhealthcare.com

Related Content

ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...